SecBot SecBot

TARA

Protara Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001359931 Biotech & Drug Discovery
$2.38 −0.15 (−5.93%)
Nov 16 4:00 PM ET · prev $2.53
Market cap
$150.2M
Micro cap
Median target
$26.00
+992% · range $18.00–30.00
1 year
−57.3%
from $5.57 · Nov 17
30 days
+2.1%
from $2.33
52-week range
$2.13–7.56
−69% from high · low Nov 5
Avg volume 20D
877.6K
shares / day
Short interest
3.24M
≈5.3% of shares · −46.9%
Days to cover
2.9
at average volume
Insider net
−$1.0M
0 buyers · 2 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 1 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 2/4

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $1.0M.

  • InstitutionsMIXED

    Q3 2026: 15 added (0 new), 13 trimmed or exited.

  • Short sellersCOVERING

    Short interest −46.9% to 3.24M shares. 2.9 days to cover, ≈5.3% of shares.

  • TrendDOWNTREND

    17% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
MARSHALL WACE, LLPDOUBLED1,543,284$4.7M
Walleye Capital LLCADD933,246$2.8M
RENAISSANCE TECHNOLOGIES LLCDOUBLED531,830$1.6M
VANGUARD PORTFOLIO MANAGEMENT LLCTRIM363,536$1.1M
MORGAN STANLEYTRIM211,030$643.6K
Fisher Asset Management, LLCADD129,612$395.3K
ALPS ADVISORS INCADD77,735$237.1K
Squarepoint Ops LLCDOUBLED68,685$209.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action May 2026
12-month targets · 6 analysts

Price is below the lowest target. Median implies +992%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
May 20, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
May 14, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Apr 29, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Mar 4, 2026JP Morgan
INITIATE
INITIATEOverweight
Feb 10, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jan 7, 2026Piper Sandler
INITIATE
INITIATEOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$1.0M
sold · 2 insiders
DateInsiderTypeValue
Jun 30, 2026
Shefferman Jesse
CEO and President
Jun 30, 2026
GIFT14,000 sh
Jun 30, 2026
Shefferman Jesse
CEO and President
Jun 30, 2026
GIFT7,000 sh
Jun 30, 2026
Shefferman Jesse
CEO and President
Jun 30, 2026
GIFT4,000 sh
Jun 30, 2026
Shefferman Jesse
CEO and President
Jun 30, 2026
GIFT5,000 sh
Jun 29, 2026
Shefferman Jesse
CEO and President
Jun 29, 2026
EXERCISE$412.0K
Jun 29, 2026
Shefferman Jesse
CEO and President
Jun 29, 2026
SELL$882.2K
Jun 15, 2026
BESHAR LUKE M
Director
Jun 15, 2026
AWARD31,000 sh
Jun 15, 2026
GARCEAU ROGER
Director
Jun 15, 2026
AWARD31,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.44-$0.46–-$0.42-1.5%$0.00
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
3,236,659
shares short
-46.9%
vs prior settlement
2.9
days to cover
≈5.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 6, 2026 SEC
Protara Therapeutics reported Q3 2026 results: net loss of $21.7M ($0.35 per share) vs $13.3M loss ($0.31) a year ago…
8-K · Impact 4/10
Nov 6, 2026 SEC
Protara Therapeutics reported a Q3 2026 net loss of $21.7M ($0.35 per share), wider than the $13.3M loss a year ago…
PRESS-RELEASE · Impact 4/10
Nov 6, 2026 Earnings
Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update
Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial
Oct 15, 2026 Press
Protara Therapeutics completed enrollment of the Phase 2b dose confirmation cohort (24 patients) in the THRIVE-3…
Impact 3/10
Sep 30, 2026 Inst.
MARSHALL WACE, LLP · DOUBLED
1,543,284 shares ($4.7M)
Sep 30, 2026 Inst.
Walleye Capital LLC · ADD
933,246 shares ($2.8M)
Jun 30, 2026 Insider
Shefferman Jesse gifted 14,000 shares
CEO and President
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

10 filings · 3 press releases · 0 bullish · 2 bearish · 8 neutral
All TARA filing & press-release reports (13)